Drug Development - the 6 Most Critical Reasons Why Drugs Are Delayed When Planning and Conducting CTA/IND Enabling Studies, New Webinar Hosted by Xtalks

TORONTO, November 5, 2018 (Newswire.com) - In this live webinar upcoming on Wednesday, November 21, 2018 at 11am EST (4pm GMT/UK), our featured speaker Robert Turcan, PhD, Head of Regulatory Affairs and Program Management at Envigo will explore the 6 most critical reasons why drugs are delayed when planning and conducting Clinical Trial Application (CTA)/Investigational New Drug Application (IND) enabling studies.

Having gathered input from a wide-ranging group of senior drug development scientists, this webinar will use clinical examples to explore what drug developers misjudge or simply overlook when seeking to bring small or large molecules out from the lab and into the clinic.

For more information or to register for this event, visit: Drug Development – The 6 Most Critical Reasons Why Drugs are Delayed When Planning and Conducting CTA/IND Enabling Studies.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Nima Rajan

Tel: +1 (416) 977-6555 ext 352

Email: [email protected]

Source: Xtalks